Piper Sandler analyst Jason Bednar raised the firm’s price target on Dentsply Sirona to $35 from $29 and keeps a Neutral rating on the shares. After speaking with management teams, the analyst believes orthodontic volumes showed some modest improvement the past few months, albeit still below year-ago levels. Implant volumes also continue to grow at a solid pace, the analyst tells investors in a research note. As such a result, Piper raised valuation multiples and price targets across its coverage of diversified dental players.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on XRAY:
- Dentsply Sirona to Host Fourth Quarter and Full Year 2022 Conference Call on February 28th
- Dentsply Sirona weighing $1B split of Wellspect HealthCare, Bloomberg reports
- Report of Dentsply weighing Wellspect sale ‘could have legs to it,’ says Piper
- Dentsply Sirona weighing possible carve-out of Wellspect, Bloomberg says
- Dentsply Sirona upgraded to Market Perform from Underperform at William Blair